Lifeward shares surge 11.6% intraday as Humana and UnitedHealthcare approve ReWalk 7 reimbursement, boosting access and revenue potential.

Lifeward surged 11.6% intraday after announcing prior authorization for the ReWalk 7 Personal Exoskeleton from Humana Medicare Advantage Plan, marking the second major U.S. Medicare Advantage provider—following UnitedHealthcare—to approve coverage. The approval expands access for 47% of Medicare Advantage enrollees, enhancing patient access to the technology and reinforcing Lifeward’s growth potential through stronger revenue and cash flow. The CEO highlighted the milestone as critical for scalable U.S. market expansion, with growing payer adoption signaling increased recognition of the exoskeleton’s clinical value. This development directly aligns with the stock’s sharp intraday increase, driven by optimism over expanded reimbursement pathways and commercial scalability.